Figure 6.

FOLFOX improves immune checkpoint blockade treatment on colon cancer. (A) Scheme of treatment. MC38-CEA2 cells were implanted subcutaneously in naïve C57BL/6 mice. After tumor was well-established (40–70 mm² in size), FOLFOX and anti-PD-1 treatment were started on the same day. Mice were injected (i.p.) with anti-PD-1 antibody (200 μg/mouse) every 3 days for 3 weeks. FOLFOX or PBS were given once weekly via i.p injection for 3 weeks. (B) Graph shows means and SEM of tumor area for n = 3–5 mice per group. (C) The frequencies of TCF-1 positive CD8 T cells (TCF-1+Db-CEAtet+CD8+) in the indicated treatment. Data is the result of combining two independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001.